Dyax Corp. Company Profile (NASDAQ:DYAX)

About Dyax Corp.

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Industry, Sector and Symbol:

• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Exchange: NASDAQ
• Symbol: DYAX
• CUSIP: 26746E10

Key Metrics:

• Previous Close: $38.41
• 50 Day Moving Average: $37.73
• 200 Day Moving Average: $29.05
• 52-Week Range: $14.06 - $38.56
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -274.36
• P/E Growth: 0.00
• Market Cap: $N/A

Additional Links:

• View DYAX on Google Finance
• View DYAX on Yahoo Finance
• View DYAX's Company Profile on Reuters
• Search for Dyax Corp. on Google

Companies Related to Dyax Corp.:

• Merck KGaA (OTCMKTS:MKGAY)
• Hospira (NYSE:HSP)
• Omnicare (NYSE:OCR)
• Opko Health (NYSE:OPK)
• Health Net (NYSE:HNT)
• WuXi PharmaTech (Cayman) (NYSE:WX)
• Hanger (NYSE:HGR)
• Savient Pharmaceuticals (NASDAQ:SVNT)
• Nobilis Health Corp (NYSE:HLTH)
• SIGA Technologies (NASDAQ:SIGA)

Earnings

Earnings History for Dyax Corp. (NASDAQ:DYAX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
2/22/2016
10/28/2015	Q315	($0.08)	($0.08)	$24.96 million	$24.70 million	View	N/A
7/29/2015	Q215	($0.04)	($0.06)	$23.40 million	$264.00 million	View	Listen
4/29/2015	Q115	($0.05)	($0.05)	$21.79 million	$20.40 million	View	N/A
2/24/2015	Q414	($0.04)	($0.02)	$19.90 million	$26.00 million	View	N/A
10/28/2014	Q314	($0.06)	($0.01)	$15.70 million	$22.00 million	View	N/A
7/29/2014	Q214	($0.05)	($0.02)	$14.13 million	$19.59 million	View	N/A
4/30/2014		($0.05)	($0.05)			View	N/A
2/28/2014	Q413	($0.04)	($0.02)	$15.84 million	$16.90 million	View	N/A
10/22/2013	Q313	($0.05)	($0.06)	$14.80 million	$13.70 million	View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.04)	($0.04)	($0.04)
Q2 2016	1	($0.04)	($0.04)	($0.04)
Q3 2016	1	($0.03)	($0.03)	($0.03)
Q4 2016	2	($0.01)	$0.01	$0.00

(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dyax Corp. (NASDAQ:DYAX)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
9/10/2015	Thomas L Kempner	Director	Sell	6,000	$22.47	$134,820.00
8/28/2015	Thomas L Kempner	Director	Sell	17,947	$23.83	$427,677.01
8/18/2015	Thomas L Kempner	Director	Sell	18,035	$23.83	$429,774.05
8/13/2015	Thomas L Kempner	Director	Sell	4,848	$23.81	$115,430.88
7/20/2015	Henry E Blair	Director	Sell	50,000	$27.05	$1,352,500.00
6/8/2015	David J Mclachlan	Director	Sell	75,000	$25.63	$1,922,250.00
3/6/2015	Andrew D Ashe	EVP	Sell	2,400	$15.50	$37,200.00
3/5/2015	Burt A Adelman	CMO	Sell	9,375	$15.66	$146,812.50
3/5/2015	George V Migausky	CFO	Sell	5,000	$15.86	$79,300.00
3/5/2015	Gustav Christensen	CEO	Sell	6,250	$15.86	$99,125.00
2/26/2015	Andrew D Ashe	EVP	Sell	1,500	$15.34	$23,010.00
1/2/2015	Burt A Adelman	CMO	Sell	75,000	$14.05	$1,053,750.00
12/5/2014	Thomas L Kempner	Director	Sell	14,764	$13.79	$203,595.56
11/21/2014	Thomas L Kempner	Director	Sell	100,000	$13.20	$1,320,000.00
9/12/2014	Thomas L Kempner	Director	Sell	12,400	$11.00	$136,400.00
8/26/2014	Thomas L Kempner	Director	Sell	37,000	$10.39	$384,430.00
8/19/2014	Thomas L Kempner	Director	Sell	113,755	$9.67	$1,100,010.85
8/7/2014	Thomas L Kempner	Director	Sell	33,190	$9.25	$307,007.50
6/13/2014	George V Migausky	CFO	Sell	16,000	$8.26	$132,160.00
3/5/2014	Henry Blair	Director	Sell	150,000	$10.46	$1,569,000.00
3/3/2014	Andrew Ashe	EVP	Sell	30,000	$10.00	$300,000.00
3/3/2014	Burt Adelman	CMO	Sell	55,000	$9.68	$532,400.00
2/26/2014	Andrew Ashe	VP	Sell	2,723	$10.10	$27,502.30
12/5/2013	Thomas Kempner	Director	Sell	400,000	$8.37	$3,348,000.00
8/13/2013	Andrew Ashe	VP	Sell	32,500	$4.30	$139,750.00
5/16/2013	Marc D Kozin	Director	Buy	22,971	$2.46	$56,508.66
2/25/2013	George V Migausky	CFO	Sell	4,275	$3.28	$14,022.00
2/25/2013	Ivana Magovcevic	COO	Sell	4,015	$3.24	$13,008.60

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dyax Corp. (NASDAQ:DYAX)

Date	Headline
	Business Briefs - Your Houston News (NASDAQ:DYAX) www.yourhoustonnews.com - September 26 at 4:53 PM
	Stocks To Watch: Marathon Petroleum Corporation (MPC), Merrimack Pharmaceuticals, Inc. (MACK), J. C. Penney ... - iStreetWire (NASDAQ:DYAX) istreetwire.com - September 26 at 9:26 AM
	Eye Catching Stocks: Merrimack Pharmaceuticals, Inc. (MACK), J. C. Penney Company, Inc. (JCP), Kinder Morgan, Inc ... - iStreetWire (NASDAQ:DYAX) istreetwire.com - September 24 at 9:21 AM
	Bayh reflects on return to the fray: Former governor faces Todd Young in November - Vincennes Sun Commercial (NASDAQ:DYAX) www.suncommercial.com - September 24 at 9:21 AM
	Bayh reflects on return to the fray - Evening News and Tribune (NASDAQ:DYAX) www.newsandtribune.com - September 21 at 5:13 PM
	Bayh reflects on return to the fray (NASDAQ:DYAX) www.newsandtribune.com - September 21 at 9:01 AM
	Bayh reflects on return to the fray - Kokomo Tribune (NASDAQ:DYAX) www.kokomotribune.com - September 19 at 9:23 AM
	Shire : District Court Issues Ruling in Hatch Waxman Case Regarding Shire's LIALDA® (NASDAQ:DYAX) www.4-traders.com - September 17 at 9:26 AM
	Dyax Corp. - Medical Equipment - Deals and Alliances Profile - New Report Available (NASDAQ:DYAX) reports.pr-inside.com - September 13 at 9:37 AM
	Next Generation Antibody Therapeutics Market with steady growth at a CAGR of 13.0% by 2022 - Medgadget (blog) (NASDAQ:DYAX) www.medgadget.com - September 9 at 4:34 PM
	Placing Dyax Corp. (NASDAQ:DYAX) Shares Under the Microscope - Post News (NASDAQ:DYAX) www.kentuckypostnews.com - September 8 at 8:34 AM
	Santhera Announces Financial Results for the First Half Year 2016 and Reports Solid Sales Growth - Company Starts ... - Yahoo Finance (NASDAQ:DYAX) finance.yahoo.com - September 7 at 8:02 AM
	SANTHERA PHARMACEUTICALS HOLDING AG (NASDAQ:DYAX) www.finanznachrichten.de - September 6 at 9:34 AM
	Santhera Announces Financial Results for the... (NASDAQ:DYAX) www.benzinga.com - September 6 at 9:34 AM
	Shire : U.S. Securities and Exchange Commission filings (NASDAQ:DYAX) www.4-traders.com - September 5 at 9:21 AM
	Stock in Review: Taking a Closer Look at Dyax Corp. (NASDAQ:DYAX) Shares - Post News (NASDAQ:DYAX) www.kentuckypostnews.com - September 1 at 8:31 AM
	Stocks To Watch: Merrimack Pharmaceuticals, Inc. (MACK), Catalent, Inc. (CTLT), LaSalle Hotel Properties (LHO) - iStreetWire (NASDAQ:DYAX) istreetwire.com - August 31 at 9:33 AM
	Shares of DYAX Up 59.4% Since Uptrend Call on Shares (NASDAQ:DYAX) www.mysmartrend.com - August 30 at 4:48 PM
	BBergCV.2015.12 (NASDAQ:DYAX) www.slideshare.net - August 29 at 8:52 PM
	Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% is Now Available in the U.S. (NASDAQ:DYAX) www.presseportal.de - August 29 at 3:45 PM
	Is it Time to Buy Dyax Corp. (NASDAQ:DYAX)? The Consensus Is In - Post News (NASDAQ:DYAX) www.kentuckypostnews.com - August 25 at 4:46 PM
	Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye (NASDAQ:DYAX) www.presseportal.de - August 25 at 9:41 AM
	Sell-side & Crowd View on Dyax Corp. (NASDAQ:DYAX) - Post News (NASDAQ:DYAX) www.kentuckypostnews.com - August 20 at 8:10 AM
	Stocks on the Move: Intrexon Corporation (XON), Waste Management, Inc. (WM), Merrimack Pharmaceuticals, Inc ... - iStreetWire (NASDAQ:DYAX) istreetwire.com - August 18 at 4:47 PM
	Can Earnings Grow for Dyax Corp. (NASDAQ:DYAX)? - Post News (NASDAQ:DYAX) www.kentuckypostnews.com - August 18 at 4:47 PM
	Crowd & Street Analysis on Dyax Corp. (NASDAQ:DYAX) - Post News (NASDAQ:DYAX) www.kentuckypostnews.com - August 18 at 7:34 AM
	Stocks Buzz: U.S. Silica (SLCA), Merrimack Pharmaceuticals (MACK) Prologis (PLD) - iStreetWire (NASDAQ:DYAX) istreetwire.com - August 11 at 4:51 PM
	New Broker Ratings For Dyax Corp. (DYAX) - FTSE News (NASDAQ:DYAX) www.ftsenews.co.uk - August 10 at 11:58 AM
	Shire : VONVENDI, The First and Only Recombinant Treatment for Adults Affected by Von Willebrand Disease, Launches in the U.S. (NASDAQ:DYAX) www.4-traders.com - August 9 at 7:58 AM
	Stocks Trend Analysis: CBRE Group, Inc. (CBG) Merrimack Pharmaceuticals, Inc. (MACK) Dick's Sporting Goods Inc ... - iStreetWire (NASDAQ:DYAX) istreetwire.com - August 5 at 8:29 AM
	Dyax Corp. (DYAX) Updated Price Targets - FTSE News (NASDAQ:DYAX) www.ftsenews.co.uk - August 5 at 8:29 AM
	Hot Stock's Alert: Liberty Global plc – Class A Ordinary Shares ... - NYSE Journal (press release) (NASDAQ:DYAX) stockznews.com - August 4 at 8:01 AM
	Shire on track for $20b in sales by 2020 (NASDAQ:DYAX) www.bostonglobe.com - August 2 at 4:53 PM
	Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook - PR Newswire (press release) (NASDAQ:DYAX) www.prnewswire.com - August 2 at 9:33 AM
	Shire chief says drug maker on track for $20 billion in sales by 2020 - The Boston Globe (NASDAQ:DYAX) www.bostonglobe.com - August 2 at 9:33 AM
	How Will Shire's ADHD Franchise Perform in 2Q16? - Market Realist (NASDAQ:DYAX) marketrealist.com - July 27 at 10:26 PM
	Shire : ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress of the World Federation of Hemophilia (NASDAQ:DYAX) www.4-traders.com - July 26 at 8:52 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Dyax Corp. (NASDAQ:DYAX) - TGP (NASDAQ:DYAX) telanaganapress.com - July 21 at 8:13 AM
	Dyax Corp. (NASDAQ:DYAX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:DYAX) www.engelwooddaily.com - July 20 at 8:11 AM
	Trading Performance and Target Watch for Dyax Corp. (NASDAQ:DYAX) - Press Telegraph (NASDAQ:DYAX) presstelegraph.com - July 18 at 4:51 PM
	Burlington Sends Mixed Signals - Banker & Tradesman (NASDAQ:DYAX) www.bankerandtradesman.com - July 17 at 4:26 PM
	Burlington Sends Mixed Signals (NASDAQ:DYAX) www.bankerandtradesman.com - July 17 at 9:15 AM
	Crowd Rating and Earnings Recap for Dyax Corp. (NASDAQ:DYAX) - Telanagana Press (NASDAQ:DYAX) telanaganapress.com - July 15 at 11:57 AM
	Three Movers to Watch for: RSP Permian, Inc. (RSPP), ZIOPHARM Oncology, Inc. (ZIOP), Merrimack Pharmaceuticals ... - iStreetWire (NASDAQ:DYAX) istreetwire.com - July 14 at 4:22 PM
	Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta - TheStreet.com (NASDAQ:DYAX) www.thestreet.com - July 14 at 4:22 PM
	Dyax Corp. (DYAX) Current Analyst Ratings - Fiscal Standard (NASDAQ:DYAX) www.fiscalstandard.com - July 13 at 9:59 PM
	Dyax Corp. (NASDAQ:DYAX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:DYAX) www.engelwooddaily.com - July 13 at 8:57 AM
	Drug-Induced Angioedema (NASDAQ:DYAX) www.medscape.com - July 10 at 4:31 PM
	Drug-Induced Angioedema - Medscape (NASDAQ:DYAX) www.medscape.com - July 8 at 4:43 PM
	Global Breast Cancer Monoclonal Antibodies Market 2016- Amgen, Biocad, Biocon, Celltrion Pharm, CuraGen ... - cHollywood News Portal (press release) (NASDAQ:DYAX) chollywood.info - July 6 at 4:48 PM

Social

Dyax Corp. (NASDAQ:DYAX) Chart for Thursday, September, 29, 2016